Navigation Links
Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
Date:5/9/2011

BETHLEHEM, Pa., QUEENSLAND, Australia and BEIJING, May 9, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the formation of its Pacific Rim commercialization team to expand its presence in Australia and China.

Members of Saladax's Pacific Rim commercialization team include:

  • Yunying Li, Ph.D. (Saladax Biomedical, Inc.) – Dr. Li, Director of Market Development, Asia, with Saladax Biomedical, has held leadership roles in the Company since 2004.  Until 2010, she served as Research Group Leader, supervising product development efforts of the MyCare™ assay development group.  Prior to Saladax, Dr. Li was a senior research scientist at OraSure Technologies, Inc.  Dr. Li has relocated to Beijing where, utilizing her technical experience with the MyCare line and her cultural ties in China, she will lead the establishment of Saladax's commercial presence in this important market.  

  • Patrick Cook (Macarthur Cook Group Pty Ltd) – Mr. Cook is Principal at Macarthur Cook Group Pty Ltd, a privately held company in Queensland, Australia, which provides business development, education and training services.  Mr. Cook's extensive experience in the Australian diagnostic industry will help Saladax expand its sales and marketing efforts in Australia.  Mr. Cook serves as director and board member of IVD Australia Ltd., a leader in Australia's in vitro diagnostic industry.  He has worked with multiple international and local organizations including Roche Diagnostics, Quidel, Abbott Diagnostics and Royal Brisbane & Women's Hospital.

"With Dr. Li's extensive experience working with Saladax and Mr. Cook's significant knowledge and recognition in the diagnostics industry, we are confident we will successfully commercialize Saladax's assays in China and Australia," said Edward L. Erickson, president and CEO of Saladax.  

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Farrell Denby
fdenby@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... 2016  New research by the CVS Health ... the U.S. Department of Health and Human Services, ... Response (ASPR), published online today in JAMA ... encourage patients with chronic conditions to refill medications ... also affirms that public-private partnerships can facilitate timely ...
(Date:12/5/2016)... 5, 2016 For the third consecutive year, ... Human Rights Campaign Foundation,s (HRC) annual ... national benchmarking tool used to rate companies on policies ... employee equality. For the last 15 years, ... gauge their equality efforts, culture and business practices. The ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... portal for all the knowledge resources, including white papers, guides, handbooks, case studies, ... , To access more than 9,000 documents, webinars and videos available online, ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life ... story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted ... looking for creative outlets, Carolyn gravitated toward writing through the inspiration of her ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. Zubinas ... thin. The beauty of the Lithuanian language and its poetry inspired him ... book, Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever ...
Breaking Medicine News(10 mins):